NASHVILLE, Tenn., March 1, 2023 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") announced today that Lucinda "Cindy" Baier, President and Chief Executive Officer and Dawn Kussow, Executive Vice President & Chief Financial Officer will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023.
The Brookdale fireside chat will begin at 11:15 am ET, and the live webcast can be accessed through the Company's website at www.brookdaleinvestors.com as well as by clicking here.
A replay of the webcast will be available on the Company's website until April 14, 2023.
About Brookdale Senior Living
Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care and services in an environment that feels like home. The Company's expertise in healthcare, hospitality and real estate provides residents with opportunities to improve wellness, pursue passions and stay connected with friends and loved ones. Brookdale, through its affiliates, operates and manages 673 communities in 41 states as of December 31, 2022, with the ability to serve more than 60,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit www.brookdale.com or connect with Brookdale on Facebook or Twitter
Last Trade: | US$5.16 |
Daily Change: | 0.08 1.58 |
Daily Volume: | 245,757 |
Market Cap: | US$1.030B |
December 09, 2024 November 11, 2024 November 06, 2024 September 30, 2024 September 10, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB